Understanding the spatial characteristics of ovarian cancer
Spatial Radiogenomics of Ovarian Cancer: Implementation of a Lesion-specific 3D-printed Mould Pipeline in the Clinical Workflow for Image-guided Tissue Multi-sampling of Ovarian Tumours
This study is trying to see how different patterns in ovarian cancer tissue can help doctors create more personalized treatments for patients with High Grade Serous Ovarian Carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Roma) |
| Trial ID | NCT06324175 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on High Grade Serous Ovarian Carcinoma (HGSOC) and aims to explore the biological spatial and temporal heterogeneity of the disease. By utilizing advanced imaging techniques and radiomics, the study seeks to capture complex patterns related to tissue microstructure, which are often overlooked in traditional histological evaluations. The integration of imaging data with clinical information, liquid biopsies, and genomic data may enhance the prediction of treatment responses and outcomes for patients. The goal is to develop personalized treatment strategies that address the molecular heterogeneity of tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with suspected High Grade Serous Ovarian Carcinoma scheduled for primary or interval debulking surgery.
Not a fit: Patients with early-stage ovarian cancer or non-serous high grade epithelial ovarian cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective personalized treatments for patients with ovarian cancer.
How similar studies have performed: Other studies utilizing radiogenomics and imaging techniques have shown promise in improving treatment outcomes, suggesting this approach may be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with suspected HGSOC scheduled to undergo primary debulking surgery (PDS) or interval debulking surgery (IDS) will be recruited in the study. Prior histopathological confirmation of HGSOC will be required for IDS. The PDS cases without prior histological diagnosis will be selected on the basis of clinical suspicion (elevated serum CA125 and CT imaging). Exclusion Criteria: * Patients less than 18 Years old * Pregnancy * Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer) * Early stage disease (I and II stage) * CT or MRI scan not available
Where this trial is running
Roma
- Advanced Radiology Center — Roma, Italy (Recruiting)
Study contacts
- Principal investigator: Camilla Panico, Dr — Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Study coordinator: Camilla Panico, Dr.
- Email: camilla.panico@policlinicogemelli.it
- Phone: +390630158637
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.